FOR IMMEDIATE RELEASE FDA EXTENDS MARKETING EXCLUSIVITY FOR INOMAX® Clinton, NJ, January 5, 2011– Ikaria, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted INOMAX® (nitric oxide) for i - Dysplasia - Document - PDFSEARCH.IO

First Page	Meta Content
	FOR IMMEDIATE RELEASE FDA EXTENDS MARKETING EXCLUSIVITY FOR INOMAX® Clinton, NJ, January 5, 2011– Ikaria, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted INOMAX® (nitric oxide) for i Add to Reading List Document Date: 2011-06-28 11:53:07 Open Document File Size: 65,53 KB Share Result on Facebook City Madison / Seattle / Port Allen / / Company Ikaria Inc. / / Country Puerto Rico / Japan / Canada / Australia / Mexico / / Event M&A / FDA Phase / / IndustryTerm manufacturing facility / drug product / treatment of hypoxic respiratory failure / gas mixtures / treatment for hepatorenal syndrome / / MedicalCondition bronchopulmonary dysplasia / pulmonary hypertension / airway inflammation / subsequent congestive heart failure / lung injury / hypoxic respiratory failure / Methemoglobinemia / acute myocardial infarction / / MedicalTreatment ECMO / extracorporeal membrane oxygenation / / Organization U.S. Food and Drug Administration / FDA / / Person Clinton / / Product INOMAX / INOtherapy® / INOMAX® (nitric oxide) / / ProvinceOrState Wisconsin / Louisiana / Washington / / Technology drug-delivery system / / URL www.ikaria.com / www.inomax.com / / SocialTag Intensive care medicine Hypertension Neurotransmitters Nitric oxide Nitrogen metabolism Pulmonary hypertension Extracorporeal membrane oxygenation Respiratory system Bronchopulmonary dysplasia Medicine

FOR IMMEDIATE RELEASE FDA EXTENDS MARKETING EXCLUSIVITY FOR INOMAX® Clinton, NJ, January 5, 2011– Ikaria, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted INOMAX® (nitric oxide) for iAdd to Reading List